Eradicates the
targeted pathogens
Tyuxt injection is effective in reducing postoperative wounds and urinary tract infections. It contains sulbactam that enhances ceftriaxone’s ability to kill bacteria by inhibiting beta-lactamase enzymes. Sulbactam treatment for skin and soft tissue infections in children showed 100% clinical and bacteriological response. Ceftriaxone treatment was also effective in 93% of patients. It is well-tolerated and safe to use.
Eliminates the
Set Pathogens
Tyuxt injection reduces postoperative wounds and urinary tract infections. It contains sulbactam, which enhances ceftriaxone’s bacteria-killing ability by inhibiting beta-lactamase enzymes. Sulbactam treated 100% of skin and soft tissue infection patients effectively, while ceftriaxone treated 93% of patients. It has a good safety profile and is well-tolerated.
- More effective than gentamicin/metronidazole prophylaxis in reducing wounds & UTI after bowel operations (1)
- Sulbactam inhibited the beta-lactamase degradation of ceftriaxone and enhanced the killing by ceftriaxone (2)
- Clinical & bacteriological response was satisfactory in 100% of Sulbactam treated patients & in 93% of the ceftriaxone-treated patients of SSTI in children (3)
- High tolerability & safety profile
1. Dis Colon Rectum 1993 Sept; 36(9): 326-33 | 2. Antimicrobials Agents Chemotherapy 1990 Apr; 34(4): 581-6 | 3. Pediatr Infec Dis 1989 Sept; 8(9): 605-10
When you feel
the Resistant
Pathogens are set
- Well-tolerated and safe to use
- High clinical and bacteriological response rate
- Enhanced ability to kill bacteria
